Hyaluronidase contributes to infection by:

Instructions: Read the exhibits carefully, then complete the 5 required deliverables. Show clear, auditor-ready reasoning consistent with relevant ASC 820, PCAOB AS 2501, AS 1210, and relevant financial analysis concepts. Background (case facts): You are the senior on the audit of Redwood Medical Devices, Inc. (RMD) for the year ended 12/31/20X5. On 10/1/20X5, RMD acquired PulsePath Diagnostics and recorded a developed technology intangible asset. Management measured fair value at 12/31/20X5 using an income approach (DCF of after-tax cash flows attributable to the technology). The recorded fair value at 12/31/20X5 is $64.0 million. What you are given (Exhibits): Exhibit 1 — Management’s key assumptions (12/31/20X5 measurement date) Projection period: 5 years (20X6–20X10) Revenue attributable to the technology: $95.0M in 20X6 Revenue growth (before obsolescence): 8% (20X7), 6% (20X8), 5% (20X9), 4% (20X10) Obsolescence/decay factor: 2% per year (applied to reduce revenue each year) EBITDA margin on attributable revenues: 24% each year Tax rate: 25% Working-capital investment: 1% of incremental revenue each year (increase in NWC is a use of cash) Reinvestment: Capex = 3% of revenue; Depreciation = 2% of revenue Discount rate (after-tax): 10.0% Terminal value: no terminal value (technology assumed to have finite remaining life after 20X10) Exhibit 2 — Market / contradictory evidence available to the audit team Peer benchmarking (similar mid-market med-device companies): after-tax WACC 10.5%–12.0% Recent RMD debt refinancing (11/15/20X5): 7.8% pre-tax yield (secured) Industry outlook: pricing pressure expected and accelerating product cycles (higher obsolescence risk) Exhibit 3 — “Model check” observation from your walkthrough The model labels “Discount rate = 10.0%,” but the discount factors provided by management appear closer to 9.0%. Student requirements: Required (deliverables): Mechanics & internal-consistency tests (Model integrity): Identify and explain at least one (1) mechanical error or internal inconsistency indicated in the exhibits and state the audit implication (what you would do next). ASC 820 market participant evaluation (incl. disclosures): Using Exhibit 2, identify at least one (1) way management’s inputs may not reflect market participant assumptions. Describe what evidence you would obtain and how you would evaluate contradictory evidence. State the disclosure implication (e.g., significant unobservable input and measurement uncertainty). Reasonable range/sensitivity (incl. disclosure linkage): Build a reasonable range using at least one (1) alternative input (choose from discount rate, obsolescence, margin, or reinvestment). Explain why the input is a key driver and conclude what sensitivity/disclosure statement a user should see (directionality + magnitude, not boilerplate). Specialist (AS 1210 concept) (incl. disclosures): State whether you would involve a valuation specialist and what you (the audit team) must still evaluate. State whether the use of a specialist or the level of estimation uncertainty changes the disclosure emphasis (e.g., highlighting measurement uncertainty / Level 3 nature). One-page “audit-ready DCF memo” (required): Draft a one-page memo that synthesizes Requirements 1–4 into an auditor-ready conclusion. Your memo must include: Objective & scope: asset, valuation date, method used (income approach / DCF), and recorded amount. Risk assessment (what could be wrong): significant assumptions and mechanics risks (tied directly to Req. 1–4). Procedures performed (what you did): Model integrity/mechanics tests performed and results (Req. 1) Market participant evaluation and how you addressed contradictory evidence (Req. 2) Sensitivity / reasonable range approach and the alternative input selected (Req. 3) Specialist involvement decision and what the audit team evaluated/retained responsibility for (Req. 4) Results & contradictory evidence resolution: summarize how (if at all) corrections or contradictory evidence affected your evaluation. Conclusion (AS 2501-style): whether the estimate is reasonable as recorded, reasonable within a range (state the range), or requires adjustment (quantify the proposed adjustment). Key disclosure considerations (bullets): pull through the disclosure implications you identified in Requirements 2–4.  

Management supports a discount rate with an internal memo (no citations). The auditor obtains a third-party benchmarking report whose range includes management’s rate, but the report is dated well before the measurement date and market spreads changed materially during the year. The best conclusion is:

Which item is most directly “contradictory evidence” under AS 2501 (i.e., evidence that challenges a key input and should change testing or conclusions)?

Match the word or two-word phrase that best describes the shape of the listed molecules?

Select all sp2 hybridized carbon atoms in this molecule. hybrid.jpg

A small part of a crystal lattice is sketched below. The unit cell is outlined in red. crystal.jpg How many atoms of each type are in the unit cell?

Which of the following lists of elements is correctly ordered in terms of decreasing electronegativity?

Identify all the sp3 hybridized carbon atoms in this molecule. Advanced Theories of Covalent Bonding I 3-1.jpg

Select the Lewis dot diagram for a Br+ cation.